🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 17 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
30/01/2009 6,30 6,30 4,62 5,22 -25,00% 26,67% 330.533
29/01/2009 7,50 7,50 6,96 6,96 -7,20% 7,20% 21.633
28/01/2009 7,20 7,92 7,20 7,50 +1,63% 10,00% 28.133
27/01/2009 7,62 8,16 7,32 7,38 -9,56% 11,02% 31.250
26/01/2009 8,16 8,40 7,62 8,16 +0,74% 9,56% 37.467
23/01/2009 7,80 8,76 7,74 8,10 +4,65% 13,08% 50.850
22/01/2009 8,64 9,06 7,74 7,74 -8,51% 15,28% 77.033
21/01/2009 8,40 9,30 6,90 8,46 +9,30% 28,57% 161.183
20/01/2009 6,96 7,98 6,48 7,74 +15,18% 21,55% 122.967
16/01/2009 7,14 8,64 6,48 6,72 -2,61% 30,25% 144.850
15/01/2009 5,64 7,08 5,46 6,90 +22,34% 28,72% 125.883
14/01/2009 5,82 5,82 5,46 5,64 -3,09% 6,19% 17.967
13/01/2009 5,52 5,82 5,10 5,82 +14,12% 13,04% 58.250
12/01/2009 4,92 5,16 4,86 5,10 +0,00% 6,10% 6.233
09/01/2009 5,40 5,52 5,10 5,10 -2,30% 7,78% 25.100
08/01/2009 4,86 5,28 4,56 5,22 +10,13% 14,81% 33.917
07/01/2009 5,10 5,22 4,50 4,74 -7,06% 14,12% 70.617
06/01/2009 4,50 5,22 4,44 5,10 +18,06% 17,33% 101.100
05/01/2009 4,20 4,44 4,14 4,32 +5,88% 7,14% 44.983
02/01/2009 3,90 4,14 3,84 4,08 +3,03% 7,69% 22.983
31/12/2008 3,78 4,02 3,72 3,96 +4,76% 7,94% 51.217
30/12/2008 3,90 3,96 3,42 3,78 -1,56% 13,85% 55.333
29/12/2008 3,78 4,02 3,72 3,84 +4,92% 7,94% 27.083
26/12/2008 4,50 4,50 3,60 3,66 -8,96% 20,00% 90.917
24/12/2008 4,08 5,64 3,90 4,02 +36,73% 42,65% 206.350
23/12/2008 3,00 3,12 2,88 2,94 -2,00% 8,00% 56.400
22/12/2008 2,88 3,00 2,76 3,00 +4,17% 8,33% 27.767
19/12/2008 2,88 3,00 2,88 2,88 +0,00% 4,17% 30.700
18/12/2008 3,24 3,24 2,88 2,88 -12,73% 11,11% 46.750
17/12/2008 3,36 3,36 3,06 3,30 -3,51% 8,93% 21.150